Analysis of spermidine's effect on coronary heart disease risk using bidirectional Mendelian randomization and LC-MS/MS.

IF 2.5 3区生物学

Hereditas Pub Date : 2025-09-26 DOI:10.1186/s41065-025-00568-4

Tianyi Wang, Li Lin, Yaodong Ding, Yang Zhang, Zehao Zhao, Ruixiang Feng, Yingxuan Bai, Zhennan Li, Yuncong Shi, Na Li, Yong Zeng

{"title":"Analysis of spermidine's effect on coronary heart disease risk using bidirectional Mendelian randomization and LC-MS/MS.","authors":"Tianyi Wang, Li Lin, Yaodong Ding, Yang Zhang, Zehao Zhao, Ruixiang Feng, Yingxuan Bai, Zhennan Li, Yuncong Shi, Na Li, Yong Zeng","doi":"10.1186/s41065-025-00568-4","DOIUrl":null,"url":null,"abstract":"Background: This study examines the causal relationship between spermidine levels and coronary artery disease (CHD) risk using a bidirectional Mendelian Randomization (MR) approach.Methods: We employed genetic variants as instrumental variables to assess the influence of genetically predicted spermidine levels on CHD risk and vice versa. Data for the MR analysis were sourced from the UK Biobank and genome-wide association study datasets, focusing on single nucleotide polymorphisms (SNPs) associated with spermidine levels and CHD. The study also utilized liquid chromatography-tandem mass spectrometry (LC-MS/MS) for accurate quantification of spermidine in plasma samples.Results: Our analysis identified a significant association between lower genetically predicted spermidine levels and increased CHD risk. The LC-MS/MS results supported the accurate measurement of spermidine, highlighting its feasibility as a clinical biomarker.Conclusions: The findings suggest that reduced spermidine levels may be a significant risk factor for CHD. This study supports the potential of spermidine as a biomarker for CHD risk assessment and its development as a therapeutic target. The integration of genetic and biochemical methodologies enhances our understanding of the role of spermidine in cardiovascular health and its utility in managing CHD risk.","PeriodicalId":12862,"journal":{"name":"Hereditas","volume":"162 1","pages":"189"},"PeriodicalIF":2.5000,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12465617/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hereditas","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1186/s41065-025-00568-4","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background: This study examines the causal relationship between spermidine levels and coronary artery disease (CHD) risk using a bidirectional Mendelian Randomization (MR) approach.

Methods: We employed genetic variants as instrumental variables to assess the influence of genetically predicted spermidine levels on CHD risk and vice versa. Data for the MR analysis were sourced from the UK Biobank and genome-wide association study datasets, focusing on single nucleotide polymorphisms (SNPs) associated with spermidine levels and CHD. The study also utilized liquid chromatography-tandem mass spectrometry (LC-MS/MS) for accurate quantification of spermidine in plasma samples.

Results: Our analysis identified a significant association between lower genetically predicted spermidine levels and increased CHD risk. The LC-MS/MS results supported the accurate measurement of spermidine, highlighting its feasibility as a clinical biomarker.

Conclusions: The findings suggest that reduced spermidine levels may be a significant risk factor for CHD. This study supports the potential of spermidine as a biomarker for CHD risk assessment and its development as a therapeutic target. The integration of genetic and biochemical methodologies enhances our understanding of the role of spermidine in cardiovascular health and its utility in managing CHD risk.

查看原文本刊更多论文

应用双向孟德尔随机化和LC-MS/MS分析亚精胺对冠心病风险的影响。

背景：本研究采用双向孟德尔随机化（MR）方法研究亚精胺水平与冠心病（CHD）风险之间的因果关系。方法：我们采用遗传变异作为工具变量来评估遗传预测亚精胺水平对冠心病风险的影响，反之亦然。MR分析数据来自UK Biobank和全基因组关联研究数据集，重点关注与亚精胺水平和冠心病相关的单核苷酸多态性（snp）。本研究还利用液相色谱-串联质谱（LC-MS/MS）对血浆样品中的亚精胺进行了准确定量分析。结果：我们的分析确定了遗传预测亚精胺水平较低与冠心病风险增加之间的显著关联。LC-MS/MS结果支持亚精胺的准确测量，突出了其作为临床生物标志物的可行性。结论：研究结果提示亚精胺水平降低可能是冠心病的重要危险因素。该研究支持亚精胺作为冠心病风险评估的生物标志物及其作为治疗靶点的潜力。遗传和生化方法的整合增强了我们对亚精胺在心血管健康中的作用及其在控制冠心病风险中的应用的理解。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hereditas Biochemistry, Genetics and Molecular Biology-Genetics

CiteScore

3.80

自引率

3.70%

发文量

期刊介绍： For almost a century, Hereditas has published original cutting-edge research and reviews. As the Official journal of the Mendelian Society of Lund, the journal welcomes research from across all areas of genetics and genomics. Topics of interest include human and medical genetics, animal and plant genetics, microbial genetics, agriculture and bioinformatics.